NorthStar Medical Radioisotopes Provides Updates on Corporate Progress and Upcoming Milestones

NorthStar’s Mo-99 program continues at the forefront of U.S. radioisotope production as the only commercialized producer of key medical radioisotopes molybdenum-99 (Mo-99)/technetium-99m (Tc-99m

Related Keywords

Missouri ,United States ,University Of Missouri ,Wisconsin ,Eckert Ziegler ,Radiopharm Theranostics ,Frank Scholz ,Stephen Merrick ,Northstar Beloit ,Clarity Pharmaceuticals ,Radiopharmaceutical Contract Development ,Manufacturing Organization ,Corporate Development ,Ge Healthcare ,He High Energy ,Northstar Medical Radioisotopes ,Regulatory Affairs ,Company Beloit ,Drug Administration ,Engineering Technology ,Organizational Health ,University Of Missouri Research Reactor ,Company Human Resources ,Program Management ,Chief Executive Officer ,Northstar Medical ,Radiogenix Systems ,Capella Imaging ,Monopar Therapeutics ,Missouri Research Reactor ,Accelerator Production ,United States Department ,National Nuclear Security Administration ,Isotope Processing ,Genix System ,Radiogenix System ,Genix Systems ,Targeted Copper Theranostic ,High Energy ,Drug Master File ,Aktis Oncology ,Clovis Oncology ,Curie Therapeutics ,Mariana Oncology ,Contract Development ,Radiogenix System Produced ,Pharmaceutical Diagnostics ,Its Beloit ,Chief Operating Officer ,External Affairs ,Public Relations ,Manufacturing Operations ,Supply Chain ,Advanced Radioisotope ,Monica Andersen ,Vice President ,Human Resources ,Important Risk Information ,Salivary Gland Imaging ,Nasolacrimal Drainage System Imaging ,Thyroid Imaging ,Vesicoureteral Imaging ,Medical Radioisotopes ,Radioisotope Content ,